key: cord-0753218-0a98yg1y
authors: Palomares Cabeza, Virginia; Kummer, Laura Y.L.; Wieske, Luuk; Hagen, Ruth R.; Duurland, Mariel; Konijn, Veronique A.L.; van Dam, Koos P.J.; Stalman, Eileen W.; van de Sandt, Carolien E.; Boekel, Laura; Verstegen, Niels J.M.; Steenhuis, Maurice; Rispens, Theo; Tas, Sander W.; Wolbink, Gertjan; Killestein, Joep; Kuijpers, Taco W.; van Ham, S. Marieke; Eftimov, Filip; Brinke, Anja ten; van Kempen, Zoé L.E.
title: Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
date: 2022-05-06
journal: Neurol Neuroimmunol Neuroinflamm
DOI: 10.1212/nxi.0000000000001178
sha: 9a981c082b897c39c85cea52c9efd6bfe45bd58d
doc_id: 753218
cord_uid: 0a98yg1y

OBJECTIVES: To evaluate whether a third vaccination shows an added effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple sclerosis treated with ocrelizumab or fingolimod. METHODS: This is a substudy of a prospective multicenter study on SARS-CoV-2 vaccination in patients with immune-mediated diseases. Patients with MS treated with ocrelizumab, fingolimod, and no disease-modifying therapies and healthy controls were included. The number of interferon (IFN)-γ secreting SARS-CoV-2–specific T cells at multiple time points before and after 3 SARS-CoV-2 vaccinations were evaluated. RESULTS: In ocrelizumab-treated patients (N = 24), IFN-γ–producing SARS-CoV-2–specific T-cell responses were induced after 2 vaccinations with median levels comparable to healthy controls (N = 12) and patients with MS without disease-modifying therapies (N = 10). A third vaccination in ocrelizumab-treated patients (N = 8) boosted T-cell responses that had declined after the second vaccination, but did not lead to higher overall T-cell responses as compared to immediately after a second vaccination. In fingolimod-treated patients, no SARS-CoV-2–specific T cells were detected after second (N = 12) and third (N = 9) vaccinations. DISCUSSION: In ocrelizumab-treated patients with MS, a third SARS-CoV-2 vaccination had no additive effect on the maximal T-cell response but did induce a boost response. In fingolimod-treated patients, no T-cell responses could be detected following both a second and third SARS-CoV-2 vaccination.

In ocrelizumab-treated patients with MS, a third SARS-CoV-2 vaccination had no additive effect on the maximal T-cell response but did induce a boost response. In fingolimod-treated patients, no T-cell responses could be detected following both a second and third SARS-CoV-2 vaccination.

For the latest articles, invited commentaries, and blogs from physicians around the world NPub.org/COVID19

In patients with multiple sclerosis (MS), both ocrelizumab (OCR) and fingolimod (FTY) are associated with decreased humoral responses following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. 1 Based on the decreased humoral response, patients with MS treated with OCR or FTY are offered a third SARS-CoV-2 vaccination in many countries. Given the poor humoral response, antiviral defense may be more reliant on T cells. The objective of this study was to evaluate longitudinal T-cell responses after second and third SARS-CoV-2 vaccinations in OCR-and FTY-treated patients with MS.

This is a substudy of a prospective multicenter multiarm cohort study on SARS-CoV-2 vaccination in patients with various immune-mediated inflammatory diseases (Target-to-B!). Participants were recruited from February 16, 2021 to August 20, 2021. Participants diagnosed with MS using OCR, FTY, and no diseasemodifying therapy (DMT) and healthy controls (HCs) were included. Cryopreserved peripheral blood mononuclear samples, collected before the first vaccination (OCR), after the second vaccination (OCR + FTY), and prior and 1 week after the third vaccination (OCR + FTY), were evaluated in an ELIspot for spikespecific interferon (INF-γ) T-cell response. A total of 200,000 cells were stimulated for 16 hours with Spike-1 (S1) or Spike-2 (S2) (JPT-Innovative Peptide-Solutions) peptide pools (1 μg/mL per peptide) in triplicate.

The ethics committee of the Amsterdam UMC, location AMC (2020.194), approved the study, and participants provided written informed consent. Dutch Trial register, ID: NL8900.

Data sets used during this study are available from the corresponding author on reasonable request.

Baseline information of patients with MS treated with OCR (n = 24), FTY (n = 12), and no DMT (n = 10) and healthy controls (n = 12) is summarized in Table. T-cell responses against SARS-CoV-2 S-proteins were significantly induced in OCR-treated patients after 2 vaccinations and were comparable to those in HCs and patients with MS without DMT (Figure, A) . In contrast, no T-cell responses were detectable in FTY-treated patients following 2 vaccinations.

T-cell responses in patients with MS treated with OCR (n = 8) or FTY (n = 9) were compared after the second vaccination with directly before the third vaccination and a week after the third vaccination (Figure, B) . A third vaccination upregulated SARS-CoV-2-specific T cells in OCR-treated patients but not to a higher extent than directly after the second vaccination (in 6 of 8 patients T-cell response were slightly lower after the third vaccination). In contrast, the third vaccination did not yield significant SARS-CoV-2-specific T-cell responses in FTY-treated patients. Although a very limited significant increase in SFU after the third vaccination was observed, the SFU was still in range of the baseline response of HCs and MS without DMT ( Figure 

In this study, SARS-CoV-2 T-cell responses following the second vaccination were found to be comparable in OCRtreated patients with MS, patients with MS without DMT, and HCs. We established that a third vaccination induces a recall of SARS-CoV-2 T cells in OCR-treated patients but does not further increase circulating SARS-CoV-2 T-cell numbers compared with after the second vaccination. This is in agreement with recent studies describing a T-cell recall after the third vaccination, 2,3 which was similar compared with the second vaccination for both OCRtreated patients and healthy controls. 2 T-cell responses induced by the vaccine have been demonstrated to be only minorly compromised to variants of concerns, including Omicron, both in healthy controls 4 as in OCR-treated patients. 3 In FTY-treated patients, we observed no detectable T-cell response against SARS-CoV-2 following 2 vaccinations. This is in line with previous findings that showed IFN-γ T-cell responses in only 14.3% of FTY-treated patients after 2 vaccinations. 1 In our study, T-cell responses remained absent also after 3 vaccinations. This is in contrast to previous findings in other vaccination settings, like influenza, where vaccination of FTY-treated patients induced normal T-cell responses. 5 Also, recall responses to tetanus vaccination were normal in a placebo-controlled study involving FTYtreated healthy volunteers, although responses to a novel antigen were affected. 6 Together, these data may indicate that FTY therapy affects vaccination responses to novel (neo)antigens, like SARS-CoV-2, but that recall responses to antigens exposed to before the start of FTY treatment are less affected. Despite the impaired humoral and cellular immune responses following SARS-CoV-2 vaccination in FTY-treated patients, the risk of severe COVID-19 in these patients seems similar to the general population, 7 introducing a clinical/immunologic paradox. FTY is associated with only moderate increased risk of infectious diseases, despite the FTY-induced lymphopenia. 8 A possible explanation could be that although circulatory T cells are severely reduced, the number and function of T cells in lymphoid tissue and mucosal tissues, like the lung, might not be affected.

In conclusion, in OCR-treated patients with MS, the third SARS-CoV-2 vaccination does not have an additive effect on the maximal T-cell response but does induce a booster response. In FTY-treated patients, both after a second and third SARS-CoV-2 vaccination, no SARS-CoV-2-specific T-cell responses are detected in the peripheral blood.

The authors thank the cryobiology facility of Sanquin Amsterdam for PBMC isolation. 

Humoral-and T-cell-specific immune responses to SARS-CoV-2 mRNA vaccination in patients with MS using different disease-modifying therapies

SARS-CoV-2 third vaccine immune response in MS patients treated with ocrelizumab

Omicron-specific cytotoxic T-cell responses after a third dose of mRNA COVID-19 vaccine among patients with multiple sclerosis treated with ocrelizumab

Divergent SARS CoV-2 omicronreactive T-and B cell responses in COVID-19 vaccine recipients

Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients

Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebocontrolled, parallel-group, multiple-dose study

COVID-19 infection in fingolimod-or siponimod-treated patients: case series

Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies

*These authors contributed equally to the manuscript as first authors. †These authors contributed equally as last authors. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.